GlassScriptPhysician profile
Chen-Pei Hung
NPI 1649549635
$3,165.29
in general payments reported to CMS, 2019-2025
23 companies · $651 in 2025
The $651 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $912 · 2023: $698 · 2024: $797 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.41 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $376.81 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.27 | 2021-2025 | Caplyta |
| Lundbeck LLC | $210.81 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $179.70 | 2021-2025 | Nuedexta, Abilify Asimtufii, Rexulti |
| Corium, LLC | $133.52 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $129.94 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $99.09 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $83.87 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Indivior INC. | $77.84 | 2023-2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $73.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $67.43 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $64.85 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $46.77 | 2023-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $44.91 | 2022-2024 | Loreev Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $38.97 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $30.85 | 2024 | Austedo Xr |
| Tris Pharma INC | $23.69 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.72 | 2025 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $20.46 | 2025 | |
| Collegium Pharmaceutical, INC. | $19.05 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $16.91 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen-Pei Hung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.